Oral antithrombotic therapy and gastrointestinal bleeding: The good, the bad and the ugly

International Journal of Clinical Practice

Volumn 66, Issue 1, 2012, Pages 2-4

  Riva, N ^a   Apostolakis, S ^a   Lip, G Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DABIGATRAN; PLACEBO; WARFARIN;

BRAIN HEMORRHAGE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; GASTROINTESTINAL HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; STROKE;

EID: 83755229026     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2011.02828.x     Document Type: Editorial

References (18)

1. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ,. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137: 263-72.
2. Sam C, Massaro JM, D'Agostino RB Sr, et al., Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol 2004; 94: 947-51. (Pubitemid 39349566)
3. Hanley JP,. Warfarin reversal. J Clin Pathol 2004; 57: 1132-9. (Pubitemid 39486516)
4. Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60.
5. Wiedermann CJ, Stockner I,. Warfarin-induced bleeding complications-clinical presentation and therapeutic options. Thromb Res 2008; 122 (Suppl. 2): S13-8. (Pubitemid 351783319)
6. Johnsen SP, Sørensen HT, Mellemkjoer L, et al., Hospitalisation for upper gastrointestinal bleeding associated with use of oral anticoagulants. Thromb Haemost 2001; 86: 563-8. (Pubitemid 32743267)
7. Coleman CI, Sobieraj DM, Winkler S, et al., Effect of pharmacologic therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract 2012; 66: 53-63.
8. Lip GY,. The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol. 2011; 8: 602-6.
9. Hart RG, Pearce LA, Aguilar MI,. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Ann Intern Med 2007; 146: 857-67. (Pubitemid 351650486)
10. Mant J, Hobbs FD, Fletcher K, et al., Warfarin vs. aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370: 493-503. (Pubitemid 47212371)
11. Connolly S, Pogue J, Hart R, et al., Clopidogrel plus aspirin vs. oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVEW): a randomised controlled trial. Lancet 2006; 367: 1903-12.
12. The ACTIVE Investigators. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360: 2066-78.
13. Ogilvie IM, Welner SA, Cowell W, Lip GY,. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. Thromb Haemost 2011; 106: 34-44.
14. Ahrens I, Lip GY, Peter K,. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost 2010; 104: 49-60.
15. Connolly SJ, Ezekowitz MD, Yusuf S, et al., Dabigatran vs. warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
16. van Ryn J, Stangier J, Haertter S, et al., Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010; 103: 1116-27.
17. Pengo V, Crippa L, Falanga A, et al., Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011; 106: doi: 10.1160/TH11-05-0358. [Epub ahead of print] PubMed PMID: 21946939.
18. Lip GY, Andreotti F, Fauchier L, et al., Bleeding risk assessment and management in atrial fibrillation patients: executive of a Position Document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. Thromb Haemostat 2011; doi: 10.1160/TH11-10-0690. December issue.